Katie McCallum,  —

A recent study analyzing the healthcare resource use and cost of H.P. Acthar Gel, an injectable drug used to manage multiple sclerosis (MS) relapse, demonstrated that the therapy is a viable alternative to plasmapheresis (PMP) and intravenous immunoglobin (IVIG). Annual direct healthcare costs encountered by MS patients in the U.S.

Since its approval by the U.S. Food and Drug Administration (FDA) in 2013, Tecfidera (dimethyl fumarate) has emerged as a first-line treatment for relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). While two separate clinical trials demonstrated Tecfidera’s ability to significantly reduce both the rate of relapse…